title: FKBP5 polymorphisms and antidepressant response in geriatric depression.
abstract: Genetic variation at the FKBP5 locus has been reported to affect clinical outcomes in patients treated with antidepressant medications in several studies. However, other reports have not confirmed this association. FKBP5 may regulate the sensitivity of the hypothalamic-pituitary-adrenal axis. We tested two FKBP5 single nucleotide polymorphisms (rs1360780 and rs3800373) in a sample of 246 geriatric patients treated for 8 weeks in a double-blind randomized comparison trial of paroxetine and mirtazapine. These two polymorphisms had previously been reported to predict efficacy in depressed patients treated with selective serotonin reuptake inhibitors such as paroxetine, and those treated with mirtazapine, an agent with both serotonergic and noradrenergic actions. However, we found no significant associations between these FKBP5 genetic variants and clinical outcomes. Neither mean Hamilton Depression Rating Scale scores nor time to remission or response were predicted by FKBP5 genetic variation. These results suggest that FKBP5 is unlikely to play a major role in determining antidepressant treatment outcomes in geriatric patients.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
authors.forename: Jane E
authors.initials: JE
authors.lastname: Sarginson
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
authors.forename: Laura C
authors.initials: LC
authors.lastname: Lazzeroni
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
authors.forename: Heather S
authors.initials: HS
authors.lastname: Ryan
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
authors.forename: Alan F
authors.initials: AF
authors.lastname: Schatzberg
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
authors.forename: Greer M
authors.initials: GM
authors.lastname: Murphy
mesh_terms: D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy* / Q000235:genetics*; D004311:Double-Blind Method; D005260:Female; D014644:Genetic Variation; D005853:Geriatrics / Q000379:methods*; D006801:Humans; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000078785:Mirtazapine; D017374:Paroxetine / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D017422:Sequence Analysis, DNA; D022021:Tacrolimus Binding Proteins / Q000235:genetics*; D016896:Treatment Outcome; D000099159:Tacrolimus Binding Protein 5
chemical_list: D000928:Antidepressive Agents; D008803:Mianserin; D000078785:Mirtazapine; D017374:Paroxetine; D022021:Tacrolimus Binding Proteins; D000099159:Tacrolimus Binding Protein 5
references.citation: BMC Psychiatry. 2006 Nov 02;6:52
references.pmid: 17081296
references.citation: J Psychiatr Res. 1975 Nov;12(3):189-98
references.pmid: 1202204
references.citation: Biol Psychiatry. 2006 Dec 15;60(12):1299-303
references.pmid: 17014829
references.citation: Psychiatry Res. 2007 Jul 30;152(1):37-44
references.pmid: 17383015
references.citation: Br J Soc Clin Psychol. 1967 Dec;6(4):278-96
references.pmid: 6080235
references.citation: Biol Psychiatry. 2008 Jun 15;63(12):1103-10
references.pmid: 18191112
references.citation: J Neuropathol Exp Neurol. 1997 Dec;56(12):1269-75
references.pmid: 9413275
references.citation: Psychoneuroendocrinology. 2009 Jan;34(1):99-109
references.pmid: 18829172
references.citation: Am J Geriatr Psychiatry. 2002 Sep-Oct;10(5):541-50
references.pmid: 12213688
references.citation: Nat Genet. 2004 Dec;36(12):1319-25
references.pmid: 15565110
references.citation: Br J Radiol. 2007 Dec;80 Spec No 2:S99-108
references.pmid: 18445750
references.citation: JAMA. 2008 Mar 19;299(11):1291-305
references.pmid: 18349090
references.citation: Ann N Y Acad Sci. 2008 Mar;1124:127-44
references.pmid: 18400928
references.citation: Am J Med Genet B Neuropsychiatr Genet. 2007 Dec 5;144B(8):1097-8
references.pmid: 17721930
references.citation: Pharmacogenomics. 2008 Jul;9(7):841-6
references.pmid: 18597649
references.citation: J Affect Disord. 2007 Dec;104(1-3):83-90
references.pmid: 17467808
references.citation: Am J Psychiatry. 2003 Oct;160(10):1830-5
references.pmid: 14514498
references.citation: Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1037-47
references.pmid: 18326728
references.citation: J Pathol. 2007 Jan;211(2):173-80
references.pmid: 17200939
references.citation: Drugs Aging. 2004;21(8):531-54
references.pmid: 15182217